To Develop and Implement The Scope of Medical Care for Homologous Recombination Deficient Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer of the III-IV Stages Using Maintenance Therapy With PARP Inhibitor Combined With Angiogenesis Inhibitor.
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Age ≥18-≤75 years.
• Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Possibility of performing diagnostic laparoscopy or cytoreductive surgery.
• Presence of homologous recombination deficiency (HRD).
• No contraindications to chemotherapy, or bevacizumab.
• Signed informed consent to participate in the study.
Locations
Other Locations
Belarus
N.N. Alexandrov National Caner Centre
RECRUITING
Minsk
Contact Information
Primary
Hanna Trukhan
annavladimir@rambler.ru
80291985715
Backup
Sergey Mavrichev
smavrichev71@gmail.com
Time Frame
Start Date: 2025-07-01
Estimated Completion Date: 2033-06-30
Participants
Target number of participants: 120
Treatments
Experimental: PARPi + Bev
Experimental: PARPi
Related Therapeutic Areas
Sponsors
Leads: N.N. Alexandrov National Cancer Centre